

About Synapse

The past two decades have seen an amazing exponential growth in the availability of genetic and other important biomolecular data fueled by incredible advances in measurement technologies. These breakthroughs have resulted in an increasing amount of money spent on research by industry and research papers written by academia. However, despite a few examples of new block-buster drugs, we have not witnessed a general rapid improvement in the treatment of many significant human diseases. Indeed, the numbers of new drugs approved by the FDA has actually declined over this same period.

A fundamental reason improvement in clinical outcomes does not match the pace of biological data production is that the analysis and interpretation of this data remain largely an individual activity limited by the bandwidth of an individual scientist. Drug development pipelines require a series of handoffs among many individual scientists, each with different areas of expertise. In our experience, the ability to access, understand, reformat, and reuse data, analysis methods, or models of disease at each step in the pipeline is a significant rate-limiting step, even within the confines of a single company or research institution. Additionally, much of the relevant data to answer a particular research question is spread among multiple public and private repositories. Because each pharmaceutical company and academic group protects their own data, the end result is enormous duplication of effort and missed opportunities across the industry as a whole.

Sage Bionetworks' mission is to catalyze a cultural transition from the traditional single lab, single-company, and single-therapy R&D paradigm to a model based on broad precompetitive collaboration on the analysis of large scale data in medical sciences. If this were to happen it would benefit future patients through improved treatments to diseases. It would benefit society through reduced costs of health care. It could even benefit the pharmaceutical industry, which is struggling to replace the revenue lost as old medicines go off patent production, by seeding increased innovation in the sector. Sage Bionetworks is actively engaged with academic, industrial, government, and philanthropic collaborators in developing solutions to these issues.

The technology component of Sage's solution strategy is Synapse, an informatics platform for open data-driven science. Synapse will provide support for Sage Bionetwork's own research initiatives, but more importantly serve as a public resource for the broader scientific community.

Catalyzing a transformation to truly collaborative research requires that the platform help scientists solve a series of problems that impede truly collaborative work today:

1. **Finding and using relevant data** - Frequently today scientists have difficulty just tracking down and gaining access to resources created by others, even within the confines of the same organization. Even when data is available, ~75% of the work of an analysis project is spent understanding data structures and preprocessing data for analysis. Synapse provides ways to not only make data discoverable, but push data to leverage common formats, controlled vocabularies, and annotation standards that allow data to be described and exposed to analysis unambiguously.
2. **Understanding analysis workflows** - Synapse accounts for the fact that much research is experimental and ad hoc in nature, and that hardened analysis methods only emerge over time. Tracking who has run what version of code on what version of the data in a project is the key to reproducible, and therefore improvable, research.

- To support the vision described above, a variety of types of users will need to interact with Synapse for different purposes. Initially the Synapse system will be focused on supporting the statistical or computational biologist power users in manipulating clinical and genomics data sets; over time support could grow for more biological or clinically focused researchers. Synapse leverages a web service-based architecture in which a common set of services is accessed via different sets of client applications to support a growing set of use cases over time.

Synapse CONtribute to the CURE

Home Datasets Tools Networks People Projects

Invitation to Participate

Do you know of or have you generated a dataset that you would like to have curated and quality controlled to Sage Biomarkers standards?

[Contact Us](#)

Network Generation Analysis

Overview

In this analysis, we generate a list of key datasets for the network model generation process. The methodology is based on the Rosetta Daystein network analysis.

Bad news...

Analysis: [Click a step to view its details and resources](#)

Steps:

- 1. Dataset
- 2. Information
- 3. Annotation
- 4. Data List
- 5. Survival
- 6. Expression
- 7. Network
- 8. Sample

Bad news...

1. Dataset: [Click a step to view its details and resources](#)

2. Information: [Click a step to view its details and resources](#)

3. Annotation: [Click a step to view its details and resources](#)

4. Data List: [Click a step to view its details and resources](#)

5. Survival: [Click a step to view its details and resources](#)

6. Expression: [Click a step to view its details and resources](#)

7. Network: [Click a step to view its details and resources](#)

8. Sample: [Click a step to view its details and resources](#)

For more information, please see the Synapse Vision Document or contact synapseInfo@sagebase.org.